AT
Addition Therapeutics, Inc.
SEC filingBiotechnology · South San Francisco, CA
Amount raised$28Msold at filing
Total offering$28M
Investors in the raise9count reported to the SEC
FiledDec 22, 2025first sale Dec 11, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Kathleen CollinsDirector
Jayson PunwaniDirector
Matthew PattersonDirector
Peter BisgaardDirector
Lawrence KongExecutive Officer
Jennifer LeeDirector
Laetitia SchwabDirector
Ronald ParkExecutive Officer, Director
Executive officers, directors and promoters as listed on the Form D.